Texan Capital Management’s AstraZeneca AZN Stock Holding History

Texan Capital Management’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-22,664	Closed	-$1.41M	–	107
2017 Q1	$1.41M	Sell	22,664 -5,331	-19%	-$310K	0.64%	59
2016 Q4	$1.53M	Hold	27,995	–	–	0.71%	56
2016 Q3	$1.84M	Hold	27,995	–	–	0.87%	48
2016 Q2	$1.69M	Sell	27,995 -1,419	-5%	-$82.4K	0.78%	52
2016 Q1	$1.66M	Hold	29,414	–	–	0.77%	53
2015 Q4	$2M	Hold	29,414	–	–	0.9%	43
2015 Q3	$1.87M	Buy	29,414 +583	+2%	+$38.4K	0.83%	47
2015 Q2	$1.84M	Buy	28,831 +22,806	+379%	+$1.56M	0.74%	52
2015 Q1	$412K	Hold	6,025	–	–	0.23%	86
2014 Q4	$424K	Sell	6,025 -11,740	-66%	-$841K	0.19%	91
2014 Q3	$1.27M	Buy	17,765 +2,390	+16%	+$175K	0.54%	63
2014 Q2	$1.14M	Sell	15,375 -510	-3%	-$36.9K	0.49%	69
2014 Q1	$1.03M	Sell	15,885 -170	-1%	-$11K	0.47%	71
2013 Q4	$953K	Hold	16,055	–	–	0.49%	68
2013 Q3	$834K	Hold	16,055	–	–	0.4%	72
2013 Q2	$759K	Buy	+16,055	New	+$818K	0.37%	87

Other funds holding AZN

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

EIP

Epoch Investment Partners New York $17.6B AUM 34.17% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

Texan Capital Management's AZN Position: Q2 2017 in Review

Texan Capital Management sold out of AstraZeneca (AZN) in Q2 2017, closing a stake of 22,664 shares — an estimated $1.41M sold.

Texan Capital Management first reported a position in AZN in Q2 2013 and held it in 16 quarters. The position peaked at $2M in Q4 2015. 466 funds tracked by Wall St. Rank hold AZN as of Q2 2017.

Texan Capital Management reported no remaining AstraZeneca position as of Q2 2017 after selling out during the quarter.
Texan Capital Management sold 22,664 AstraZeneca shares in Q2 2017, an estimated $1.41M.
Texan Capital Management first reported a position in AstraZeneca in Q2 2013 and held it in 16 quarters.
Texan Capital Management's AstraZeneca position peaked at $2M in Q4 2015.
466 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2017.

Based on Texan Capital Management's 13F filing for Q2 2017, filed 13 Jul 2017.